Gland Pharma Ltd

BSE: 543245 NSE: GLAND
Gland Pharma Ltd - healthcare in Medchal Malkajgiri District Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L24239TG1978PLC002276 Incorporated 20 March 1978 ROC Hyderabad HQ Medchal Malkajgiri District Hyderabad, Telangana, India
Active Listed - NSE: GLAND · BSE: 543245 Public Limited Company healthcare
Data last updated
Revenue · FY 2026
₹6,430.65 Cr
▲ 14.5% YoY
Computed EBITDA · FY 2026
₹1,945.87 Cr
▲ 31.25% YoY
Net profit · FY 2026
₹1,027.32 Cr
▲ 47.07% YoY
Authorised capital
₹56.3 Cr
Registered with MCA
Paid-up capital
₹16.5 Cr
Issued & subscribed
Open charges
None
Satisfied ₹566.83 Cr
Company age
48 yrs
Est. 1978
Employees · EPFO
4,769
Latest available

About Gland Pharma Ltd

Data last updated: 14 July 2026

Gland Pharma Ltd is a public limited company based in Medchal Malkajgiri District Hyderabad, Telangana, India, a subsidiary of Fosun Pharma Industrial Pte Ltd. It specialises in medical and laboratory equipment, a part of the broader healthcare sector. Incorporated on 20 March 1978, the company has been in operation for over 48 years.

Registered with ROC Hyderabad under CIN L24239TG1978PLC002276. Listed on BSE: 543245 and NSE: GLAND.

Capital: an authorised share capital of ₹56.3 Cr and a paid-up capital of ₹16.5 Cr. Formerly known as Gland Pharma Pvt Ltd. It is led by directors including Jia Ai Zhang and Naina Lal Kidwai.

Last AGM: 28 August 2025. Financial statements filed for year ended 31 March 2025. Office: Medchal Malkajgiri District Hyderabad, Telangana.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹6,430.65 Cr, a growth of 14.5% compared to the previous year. The net worth stands at ₹10,358 Cr (up 13.19% YoY). Total assets are valued at ₹12,511 Cr (up 11.46% YoY).

The company has a workforce of approximately 4,769 employees as per the latest available data. It operates as a subsidiary of Fosun Pharma Industrial Pte Ltd.

The company is associated with 1 brand - Gland Pharma. As per MCA filings, the company has satisfied charges of ₹566.83 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glandpharma.com.

Company Details of Gland Pharma Ltd
CIN L24239TG1978PLC002276
Registration Number 002276
Incorporation Date 20 March 1978
ROC Hyderabad
Listing Status Listed (BSE: 543245, NSE: GLAND)
Company Status Active
Date of Last AGM 28 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Fosun Pharma Industrial Pte Ltd
Compliance Status Active Compliant
Key People
Srinivas Sadu Whole-Time Director Jia Ai Zhang Director Naina Lal Kidwai Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    glandpharma.com
  • Social Media
  • Registered Address
    Sy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, Amma(M), Medchal Malkajgiri District Hyderabad, Telangana, India – 500043
  • Industry
    Healthcare, Medical & Laboratory Equipment
Company report
Gland Pharma Ltd - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Gland Pharma Ltd report

Financials, compliance, directors, charges, ownership and filings for Gland Pharma Ltd in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Gland Pharma Ltd

Gland Pharma Ltd has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1978PLC002276, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239TG1978PLC002276 Current
U24239AP1978PLC002276 Previous
U24239TG1978PLC002276 Previous

Associated Brands with Gland Pharma Ltd

Gland Pharma Ltd operates one associated brand: Gland Pharma. These brands represent Gland Pharma Ltd's diversified market presence and brand portfolio.

Brand Description Website
Gland Pharma
Generic injectable drugs are manufactured across therapeutic segments. glandpharma.com

Competitors & Alternatives of Gland Pharma Ltd

Brands and companies operating in the same space as Gland Pharma Ltd include Exela Pharma, Luoxin Pharmaceutical Group, Summit Biosciences and 5 more.

Competitor Description Location Founded
Exela Pharma Exela Pharma Sterile injectable pharmaceuticals are manufactured alongside CDMO services. Lenoir, United States, United States 2005
Luoxin Pharmaceutical Group Luoxin Pharmaceutical Group Developer and manufacturer of pharmaceutical products Linyi, China, China 2006
Summit Biosciences Summit Biosciences Nasal spray drug products are developed, manufactured, and commercialized. Lexington, United States, United States 2008
August Bioservices August Bioservices Diversified research services for clinical solutions are offered. Nashville, United States, United States 2017
ApiJect ApiJect Medicine injectors are manufactured by ApiJect for medical applications. Stamford, United States, United States 2015
Vetter Pharma Vetter Pharma CDMO specializing in aseptically prefilled syringe systems, cartridges and vials. Ravensburg, Germany, Germany 1950
INCOG BioPharma Services INCOG BioPharma Services Injectable drug products are manufactured by this biopharma CDMO. United States 2020
Nitin Lifesciences Nitin Lifesciences CMO of small volume parenteral injectables Karnal, India, India 1994

Business Activity of Gland Pharma Ltd

Gland Pharma Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Gland Pharma Ltd

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Gland Pharma Ltd

Gland Pharma Ltd is audited by Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Gland Pharma Ltd

Gland Pharma Ltd is currently managed by 8 directors, with 27 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Jia Ai Zhang
Also directs: Gland Pharma Ltd
Director 17 May 2021 5 Years 3 Months Current
Naina Lal Kidwai
Also directs: Upl Limited, Biocon Limited, Gland Pharma Ltd and 2 more
Director 17 May 2021 5 Years 3 Months Current
Essaji Goolam Vahanvati
Also directs: Gland Pharma Ltd, Agb Oils Llp, Bagh Tola Jungle Lodges Llp and 5 more
Director 30 Sep 2020 5 Years 10 Months Current
Srinivas Sadu
Also directs: Gland Pharma Ltd, Sadu Advisory Services Private Limited
Whole-Time Director 25 Apr 2019 7 Years 3 Months Current
Udo Jahannes Vetter
Also directs: Gland Pharma Ltd, Paschal Form Work (India) Private Limited
Director 07 Feb 2018 8 Years 6 Months Current
Wei Huang
Also directs: Gland Pharma Ltd
Director 04 Nov 2024 1 Years 9 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Gland Pharma Ltd FY 2026 filings available

Gland Pharma Ltd reported revenue of ₹6,430.65 Cr (up 14.5% YoY) for FY 2026.

Revenue · FY 2026
₹6,430.65 Cr ▲ 14.5%
Profit · FY 2026
₹1,027.32 Cr ▲ 47.07%
Computed EBITDA · FY 2026
₹1,945.87 Cr ▲ 31.25%
Revenue₹ Cr · Consolidated02,5005,0007,500FY 2021: ₹3,463 Cr3,463FY 2021FY 2022: ₹4,401 Cr · +27.1% YoY4,401+27.1%FY 2022FY 2023: ₹3,625 Cr · -17.6% YoY3,625-17.6%FY 2023FY 2024: ₹5,665 Cr · +56.3% YoY5,665+56.3%FY 2024FY 2025: ₹5,617 Cr · -0.9% YoY5,617-0.9%FY 2025FY 2026: ₹6,431 Cr · +14.5% YoY6,431+14.5%FY 2026
Net Profit₹ Cr · Consolidated05001,0001,500FY 2021: ₹997 Cr997FY 2021FY 2022: ₹1,212 Cr · +21.5% YoY1,212+21.5%FY 2022FY 2023: ₹781 Cr · -35.5% YoY781-35.5%FY 2023FY 2024: ₹772 Cr · -1.1% YoY772-1.1%FY 2024FY 2025: ₹699 Cr · -9.6% YoY699-9.6%FY 2025FY 2026: ₹1,027 Cr · +47.1% YoY1,027+47.1%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year01,0002,000Q1'25: ₹1,402 Cr · +16% YoY1,402+16%Q1'25Q2'25: ₹1,406 Cr · +2.4% YoY1,406+2.4%Q2'25Q3'25: ₹1,384 Cr · -10.4% YoY1,384-10.4%Q3'25Q4'25: ₹1,425 Cr · -7.3% YoY1,425-7.3%Q4'25Q1'26: ₹1,506 Cr · +7.4% YoY1,506+7.4%Q1'26Q2'26: ₹1,487 Cr · +5.8% YoY1,487+5.8%Q2'26Q3'26: ₹1,695 Cr · +22.5% YoY1,695+22.5%Q3'26Q4'26: ₹1,743 Cr · +22.3% YoY1,743+22.3%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue from Operations ₹6,430.65 Cr ₹5,616.5 Cr ₹5,664.72 Cr ₹3,624.6 Cr ₹4,400.71 Cr ₹3,462.88 Cr
Other Income ₹316.33 Cr ₹213.61 Cr ₹170.24 Cr ₹240.46 Cr ₹223.94 Cr ₹134.78 Cr
Total Income ₹6,746.98 Cr ₹5,830.11 Cr ₹5,834.96 Cr ₹3,865.06 Cr ₹4,624.65 Cr ₹3,597.65 Cr
Cost of Materials Consumed ₹2,239.75 Cr ₹1,972.48 Cr ₹2,022.14 Cr ₹1,716.75 Cr ₹2,046.86 Cr ₹1,749.16 Cr
Purchases of Stock-in-Trade ₹6.6 Cr ₹14.49 Cr ₹23.07 Cr ₹15.59 Cr ₹25.67 Cr ₹16.2 Cr
Changes in Inventories -₹3.42 Cr ₹103.41 Cr ₹127.89 Cr -₹46.92 Cr ₹36.69 Cr -₹273.49 Cr
Employee Benefit Expense ₹1,628.84 Cr ₹1,401.56 Cr ₹1,256.89 Cr ₹403.26 Cr ₹338.57 Cr ₹311.36 Cr
Finance Costs ₹33.28 Cr ₹42 Cr ₹26.2 Cr ₹7.45 Cr ₹5.24 Cr ₹3.41 Cr
Depreciation & Amortisation ₹423.67 Cr ₹377.87 Cr ₹344.57 Cr ₹146.74 Cr ₹110.3 Cr ₹98.78 Cr
Other Expenses ₹929.34 Cr ₹855.64 Cr ₹901.67 Cr ₹511.15 Cr ₹442.77 Cr ₹357.42 Cr
Total Expenses ₹5,258.05 Cr ₹4,767.45 Cr ₹4,702.42 Cr ₹2,754.02 Cr ₹3,006.09 Cr ₹2,262.84 Cr
Profit Before Exceptional Items & Tax ₹1,488.93 Cr ₹1,062.66 Cr ₹1,132.54 Cr ₹1,111.04 Cr ₹1,618.55 Cr ₹1,334.81 Cr
Exceptional Items -₹24.35 Cr ₹0 ₹0 -₹56.46 Cr ₹0 ₹0
Profit Before Tax ₹1,464.58 Cr ₹1,062.66 Cr ₹1,132.54 Cr ₹1,054.58 Cr ₹1,618.55 Cr ₹1,334.81 Cr
Total Tax Expense ₹437.26 Cr ₹364.13 Cr ₹360.08 Cr ₹273.54 Cr ₹406.89 Cr ₹337.85 Cr
Net Profit ₹1,027.32 Cr ₹698.53 Cr ₹772.46 Cr ₹781.04 Cr ₹1,211.66 Cr ₹996.96 Cr
  attributable to Owners ₹1,027.32 Cr ₹698.53 Cr ₹772.46 Cr ₹781.04 Cr ₹1,211.66 Cr ₹996.96 Cr
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹430.99 Cr ₹55.39 Cr -₹7.87 Cr -₹1.44 Cr -₹45.8 Lakh -₹87.2 Lakh
Total Comprehensive Income ₹1,458.3 Cr ₹753.91 Cr ₹764.6 Cr ₹779.61 Cr ₹1,211.21 Cr ₹996.09 Cr
EBITDA (computed) ₹1,945.87 Cr ₹1,482.53 Cr ₹1,503.31 Cr ₹1,265.23 Cr ₹1,734.09 Cr ₹1,437 Cr
Basic EPS ₹62.35 ₹42.40 ₹46.90 ₹47.44 ₹73.81 ₹63.07
Diluted EPS ₹62.28 ₹42.40 ₹46.89 ₹47.43 ₹73.64 ₹62.99
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹12,511 Cr ₹11,225 Cr ₹10,661 Cr ₹8,777.54 Cr
Non-current Assets ₹4,984.06 Cr ₹4,441.98 Cr ₹5,016.09 Cr ₹1,876.73 Cr
Current Assets ₹7,526.79 Cr ₹6,782.94 Cr ₹5,645.15 Cr ₹6,900.81 Cr
Property, Plant & Equipment ₹4,051.97 Cr ₹3,750.54 Cr ₹3,541.31 Cr ₹1,558.5 Cr
Inventories ₹1,743.89 Cr ₹1,685.22 Cr ₹1,655.24 Cr ₹1,945.3 Cr
Trade Receivables ₹1,891.38 Cr ₹1,516.53 Cr ₹1,558.69 Cr ₹871.39 Cr
Cash & Equivalents ₹3,359.11 Cr ₹2,556.21 Cr ₹357.09 Cr ₹1,908.9 Cr
Equity (Net Worth) ₹10,358 Cr ₹9,150.74 Cr ₹8,723.84 Cr ₹7,958.72 Cr
Equity Share Capital ₹16.48 Cr ₹16.48 Cr ₹16.47 Cr ₹16.47 Cr
Borrowings (Non-current) ₹69.93 Cr ₹77.66 Cr ₹106.54 Cr ₹3.26 Cr
Borrowings (Current) ₹173.44 Cr ₹191.55 Cr ₹213.24 Cr ₹56 Lakh
Total Debt (computed) ₹243.36 Cr ₹269.21 Cr ₹319.78 Cr ₹3.82 Cr
Current Liabilities ₹1,608.4 Cr ₹1,564.85 Cr ₹1,398.36 Cr ₹729.13 Cr
Total Liabilities ₹2,152.9 Cr ₹2,074.18 Cr ₹1,937.4 Cr ₹818.81 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,031.39 Cr ₹914.73 Cr ₹996.8 Cr ₹363.97 Cr ₹790.77 Cr
Investing Cash Flow ₹137.73 Cr ₹1,704.74 Cr -₹1,756.91 Cr ₹1,208.19 Cr -₹1,002.62 Cr
Financing Cash Flow -₹416.97 Cr -₹433.48 Cr -₹799.42 Cr ₹14.92 Cr ₹34.9 Cr
Capital Expenditure ₹490.76 Cr ₹384.54 Cr ₹389.93 Cr ₹220.93 Cr ₹511.33 Cr
Free Cash Flow (computed) ₹540.62 Cr ₹530.19 Cr ₹606.87 Cr ₹143.04 Cr ₹279.44 Cr
Dividends Paid ₹296.55 Cr ₹329.49 Cr ₹0 ₹0 ₹0
Net Change in Cash ₹802.9 Cr ₹2,199.12 Cr -₹1,551.81 Cr ₹1,590.08 Cr -₹173.64 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,742.79 Cr ₹1,695.36 Cr ₹1,486.88 Cr ₹1,505.62 Cr ₹1,424.91 Cr ₹1,384.05 Cr ₹1,405.83 Cr ₹1,401.71 Cr ₹1,537.45 Cr ₹1,545.16 Cr ₹1,373.42 Cr ₹1,208.69 Cr
Other Income ₹111.47 Cr ₹63.17 Cr ₹84.16 Cr ₹57.53 Cr ₹44.03 Cr ₹58.49 Cr ₹59.66 Cr ₹51.43 Cr ₹42.15 Cr ₹37.39 Cr ₹53.16 Cr ₹37.54 Cr
Total Income ₹1,854.26 Cr ₹1,758.54 Cr ₹1,571.04 Cr ₹1,563.15 Cr ₹1,468.94 Cr ₹1,442.55 Cr ₹1,465.49 Cr ₹1,453.14 Cr ₹1,579.6 Cr ₹1,582.55 Cr ₹1,426.58 Cr ₹1,246.24 Cr
Cost of Materials Consumed ₹594.07 Cr ₹529.89 Cr ₹558.43 Cr ₹557.36 Cr ₹587.57 Cr ₹437.38 Cr ₹485.88 Cr ₹461.65 Cr ₹574.69 Cr ₹464 Cr ₹517.92 Cr ₹465.53 Cr
Purchases of Stock-in-Trade ₹2.28 Cr ₹1.5 Cr ₹1.94 Cr ₹88.1 Lakh ₹3.1 Cr ₹2.15 Cr ₹2.66 Cr ₹6.58 Cr ₹6.76 Cr ₹6.38 Cr ₹6.13 Cr ₹3.79 Cr
Changes in Inventories -₹5.02 Cr ₹45.26 Cr -₹6.56 Cr -₹37.11 Cr -₹102.71 Cr ₹23.18 Cr ₹86.93 Cr ₹96.02 Cr ₹17.94 Cr ₹128.86 Cr -₹2.49 Cr -₹16.42 Cr
Employee Benefit Expense ₹411.57 Cr ₹424.2 Cr ₹385.03 Cr ₹408.04 Cr ₹373.37 Cr ₹342.86 Cr ₹329.81 Cr ₹355.53 Cr ₹351.61 Cr ₹345.33 Cr ₹304.95 Cr ₹255 Cr
Finance Costs ₹10.03 Cr ₹3.93 Cr ₹7.82 Cr ₹11.5 Cr ₹7.45 Cr ₹22.82 Cr ₹6.11 Cr ₹5.62 Cr ₹9.96 Cr ₹5.28 Cr ₹6.05 Cr ₹4.92 Cr
Depreciation & Amortisation ₹108.66 Cr ₹107.65 Cr ₹106.31 Cr ₹101.05 Cr ₹95.76 Cr ₹96.33 Cr ₹93.83 Cr ₹91.96 Cr ₹92.61 Cr ₹105.34 Cr ₹81.3 Cr ₹65.32 Cr
Other Expenses ₹226.87 Cr ₹259.64 Cr ₹234.15 Cr ₹208.69 Cr ₹216.08 Cr ₹218.53 Cr ₹203.5 Cr ₹217.53 Cr ₹227.81 Cr ₹244.2 Cr ₹222.83 Cr ₹206.83 Cr
Total Expenses ₹1,348.46 Cr ₹1,372.06 Cr ₹1,287.12 Cr ₹1,250.41 Cr ₹1,180.61 Cr ₹1,143.24 Cr ₹1,208.71 Cr ₹1,234.89 Cr ₹1,281.37 Cr ₹1,299.39 Cr ₹1,136.69 Cr ₹984.97 Cr
Profit Before Exceptional Items & Tax ₹505.8 Cr ₹386.47 Cr ₹283.92 Cr ₹312.74 Cr ₹288.33 Cr ₹299.3 Cr ₹256.78 Cr ₹218.25 Cr ₹298.23 Cr ₹283.16 Cr ₹289.89 Cr ₹261.27 Cr
Exceptional Items ₹0 -₹24.35 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹505.8 Cr ₹362.13 Cr ₹283.92 Cr ₹312.74 Cr ₹288.33 Cr ₹299.3 Cr ₹256.78 Cr ₹218.25 Cr ₹298.23 Cr ₹283.16 Cr ₹289.89 Cr ₹261.27 Cr
Total Tax Expense ₹139.12 Cr ₹100.65 Cr ₹100.23 Cr ₹97.26 Cr ₹101.79 Cr ₹94.61 Cr ₹93.25 Cr ₹74.48 Cr ₹105.81 Cr ₹91.3 Cr ₹95.81 Cr ₹67.16 Cr
Net Profit ₹366.68 Cr ₹261.48 Cr ₹183.68 Cr ₹215.48 Cr ₹186.54 Cr ₹204.69 Cr ₹163.53 Cr ₹143.76 Cr ₹192.42 Cr ₹191.86 Cr ₹194.08 Cr ₹194.1 Cr
  attributable to Owners ₹366.68 Cr ₹261.48 Cr ₹183.68 Cr ₹215.48 Cr ₹186.54 Cr ₹204.69 Cr ₹163.53 Cr ₹143.76 Cr ₹192.42 Cr ₹191.86 Cr ₹194.08 Cr ₹194.1 Cr
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹100.91 Cr ₹40.76 Cr ₹102.83 Cr ₹186.49 Cr ₹64.53 Cr -₹93.27 Cr ₹96.33 Cr -₹12.2 Cr -₹42.59 Cr ₹74.99 Cr -₹15.61 Cr -₹24.65 Cr
Total Comprehensive Income ₹467.59 Cr ₹302.23 Cr ₹286.51 Cr ₹401.97 Cr ₹251.07 Cr ₹111.42 Cr ₹259.86 Cr ₹131.57 Cr ₹149.83 Cr ₹266.84 Cr ₹178.47 Cr ₹169.46 Cr
EBITDA (computed) ₹624.49 Cr ₹498.05 Cr ₹398.05 Cr ₹425.29 Cr ₹391.54 Cr ₹418.45 Cr ₹356.72 Cr ₹315.82 Cr ₹400.8 Cr ₹393.78 Cr ₹377.23 Cr ₹331.5 Cr
Basic EPS ₹22.26 ₹15.87 ₹11.15 ₹13.08 ₹11.32 ₹12.42 ₹9.93 ₹8.73 ₹11.68 ₹11.65 ₹11.78 ₹11.79
Diluted EPS ₹22.23 ₹15.87 ₹11.15 ₹13.08 ₹11.32 ₹12.42 ₹9.93 ₹8.73 ₹11.68 ₹11.65 ₹11.78 ₹11.78
Latest 12 quarters shown of 20 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue from Operations ₹4,552.09 Cr ₹4,116.15 Cr ₹4,167.43 Cr ₹3,616.53 Cr ₹4,400.71 Cr ₹3,462.88 Cr
Other Income ₹303.9 Cr ₹215.08 Cr ₹166.67 Cr ₹240.46 Cr ₹223.94 Cr ₹134.78 Cr
Total Income ₹4,855.99 Cr ₹4,331.22 Cr ₹4,334.09 Cr ₹3,856.99 Cr ₹4,624.65 Cr ₹3,597.65 Cr
Cost of Materials Consumed ₹1,795.22 Cr ₹1,585.86 Cr ₹1,709.74 Cr ₹1,716.75 Cr ₹2,046.86 Cr ₹1,749.16 Cr
Purchases of Stock-in-Trade ₹6.6 Cr ₹14.49 Cr ₹23.14 Cr ₹15.59 Cr ₹25.67 Cr ₹16.2 Cr
Changes in Inventories -₹6.67 Cr ₹130.25 Cr ₹87.43 Cr -₹46.92 Cr ₹36.69 Cr -₹273.49 Cr
Employee Benefit Expense ₹528.82 Cr ₹439.02 Cr ₹409.95 Cr ₹399.7 Cr ₹338.57 Cr ₹311.36 Cr
Finance Costs ₹18.07 Cr ₹22.84 Cr ₹7.84 Cr ₹7.41 Cr ₹5.24 Cr ₹3.41 Cr
Depreciation & Amortisation ₹176.24 Cr ₹169.27 Cr ₹162.11 Cr ₹146.74 Cr ₹110.3 Cr ₹98.78 Cr
Other Expenses ₹565.04 Cr ₹503.91 Cr ₹528.39 Cr ₹512.85 Cr ₹442.29 Cr ₹357.38 Cr
Total Expenses ₹3,083.33 Cr ₹2,865.64 Cr ₹2,928.6 Cr ₹2,752.13 Cr ₹3,005.61 Cr ₹2,262.8 Cr
Profit Before Exceptional Items & Tax ₹1,772.66 Cr ₹1,465.59 Cr ₹1,405.5 Cr ₹1,104.86 Cr ₹1,619.04 Cr ₹1,334.85 Cr
Exceptional Items -₹24.35 Cr ₹0 ₹0 -₹56.46 Cr ₹0 ₹0
Profit Before Tax ₹1,748.31 Cr ₹1,465.59 Cr ₹1,405.5 Cr ₹1,048.4 Cr ₹1,619.04 Cr ₹1,334.85 Cr
Total Tax Expense ₹448.76 Cr ₹375.83 Cr ₹362.17 Cr ₹272.58 Cr ₹406.89 Cr ₹337.85 Cr
Net Profit ₹1,299.55 Cr ₹1,089.75 Cr ₹1,043.33 Cr ₹775.83 Cr ₹1,212.16 Cr ₹997.01 Cr
  attributable to Owners - - - - - ₹997.01 Cr
  attributable to NCI - - - - - ₹0
Other Comprehensive Income ₹6.47 Cr -₹2.93 Cr -₹1.86 Cr -₹2.25 Cr -₹38.5 Lakh -₹87.1 Lakh
Total Comprehensive Income ₹1,306.03 Cr ₹1,086.83 Cr ₹1,041.47 Cr ₹773.57 Cr ₹1,211.77 Cr ₹996.13 Cr
EBITDA (computed) ₹1,966.97 Cr ₹1,657.69 Cr ₹1,575.45 Cr ₹1,259.01 Cr ₹1,734.58 Cr ₹1,437.04 Cr
Basic EPS ₹78.88 ₹66.15 ₹63.35 ₹47.12 ₹73.84 ₹63.07
Diluted EPS ₹78.78 ₹66.15 ₹63.33 ₹47.11 ₹73.67 ₹62.99
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹11,607 Cr ₹10,422 Cr ₹9,541.09 Cr ₹8,773.18 Cr
Non-current Assets ₹5,185 Cr ₹4,654.66 Cr ₹4,969.76 Cr ₹1,884.84 Cr
Current Assets ₹6,422.22 Cr ₹5,766.96 Cr ₹4,571.33 Cr ₹6,888.34 Cr
Property, Plant & Equipment ₹1,683.94 Cr ₹1,735.86 Cr ₹1,682.47 Cr ₹1,558.5 Cr
Inventories ₹1,265.2 Cr ₹1,254.23 Cr ₹1,260.21 Cr ₹1,945.3 Cr
Trade Receivables ₹1,520.69 Cr ₹1,142.9 Cr ₹1,171.4 Cr ₹862.84 Cr
Cash & Equivalents ₹3,177.64 Cr ₹2,432.62 Cr ₹116.21 Cr ₹1,905.22 Cr
Equity (Net Worth) ₹10,810 Cr ₹9,755.1 Cr ₹8,995.29 Cr ₹7,953.3 Cr
Equity Share Capital ₹16.48 Cr ₹16.48 Cr ₹16.47 Cr ₹16.47 Cr
Borrowings (Non-current) ₹0 ₹1.11 Cr ₹2.55 Cr ₹3.26 Cr
Borrowings (Current) ₹0 ₹1.44 Cr ₹71 Lakh ₹56 Lakh
Total Debt (computed) ₹0 ₹2.55 Cr ₹3.26 Cr ₹3.82 Cr
Current Liabilities ₹633.03 Cr ₹523.77 Cr ₹414.2 Cr ₹730.2 Cr
Total Liabilities ₹797.18 Cr ₹666.52 Cr ₹545.8 Cr ₹819.88 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹1,135.23 Cr ₹1,073.67 Cr ₹1,135.97 Cr ₹367.89 Cr ₹791.29 Cr
Investing Cash Flow -₹95.56 Cr ₹1,578.2 Cr -₹2,923.92 Cr ₹1,208.22 Cr -₹1,010.23 Cr
Financing Cash Flow -₹316.18 Cr -₹339.54 Cr -₹7.4 Cr ₹14.92 Cr ₹34.9 Cr
Capital Expenditure ₹217.93 Cr ₹135.11 Cr ₹233.59 Cr ₹220.93 Cr ₹511.33 Cr
Free Cash Flow (computed) ₹917.3 Cr ₹938.56 Cr ₹902.38 Cr ₹146.96 Cr ₹279.96 Cr
Dividends Paid ₹296.55 Cr ₹329.49 Cr ₹0 ₹0 ₹0
Net Change in Cash ₹745.02 Cr ₹2,316.42 Cr -₹1,789.01 Cr ₹1,594.04 Cr -₹180.73 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,261.59 Cr ₹1,177.51 Cr ₹1,074.15 Cr ₹1,038.84 Cr ₹1,030.35 Cr ₹1,010.78 Cr ₹1,062.99 Cr ₹1,012.02 Cr ₹1,174.83 Cr ₹1,097.86 Cr ₹1,010.67 Cr ₹884.07 Cr
Other Income ₹106.36 Cr ₹60.21 Cr ₹82.59 Cr ₹54.74 Cr ₹43.72 Cr ₹65.06 Cr ₹57.8 Cr ₹48.49 Cr ₹46.96 Cr ₹43.39 Cr ₹41.11 Cr ₹35.21 Cr
Total Income ₹1,367.95 Cr ₹1,237.72 Cr ₹1,156.74 Cr ₹1,093.58 Cr ₹1,074.07 Cr ₹1,075.85 Cr ₹1,120.79 Cr ₹1,060.51 Cr ₹1,221.79 Cr ₹1,141.25 Cr ₹1,051.78 Cr ₹919.28 Cr
Cost of Materials Consumed ₹460.96 Cr ₹434.85 Cr ₹459.59 Cr ₹439.82 Cr ₹469.39 Cr ₹348.91 Cr ₹399.87 Cr ₹367.69 Cr ₹482.88 Cr ₹378.43 Cr ₹456.63 Cr ₹391.8 Cr
Purchases of Stock-in-Trade ₹2.28 Cr ₹1.5 Cr ₹1.94 Cr ₹88.1 Lakh ₹3.1 Cr ₹2.15 Cr ₹2.67 Cr ₹6.58 Cr ₹6.83 Cr ₹6.38 Cr ₹6.13 Cr ₹3.79 Cr
Changes in Inventories ₹21.55 Cr ₹27.93 Cr -₹41.93 Cr -₹14.22 Cr -₹67.28 Cr ₹25.53 Cr ₹67.74 Cr ₹104.26 Cr ₹26.97 Cr ₹103.7 Cr -₹22.74 Cr -₹20.49 Cr
Employee Benefit Expense ₹133.96 Cr ₹134.14 Cr ₹132.28 Cr ₹128.44 Cr ₹119.7 Cr ₹105.36 Cr ₹106.29 Cr ₹107.68 Cr ₹107.87 Cr ₹99.29 Cr ₹99.88 Cr ₹102.91 Cr
Finance Costs ₹6.17 Cr ₹50.2 Lakh ₹3.97 Cr ₹7.44 Cr ₹3.45 Cr ₹18.31 Cr ₹17.2 Lakh ₹91.1 Lakh ₹4.53 Cr ₹79.9 Lakh ₹91.4 Lakh ₹1.6 Cr
Depreciation & Amortisation ₹43.11 Cr ₹44.53 Cr ₹44.84 Cr ₹43.77 Cr ₹43.07 Cr ₹43.77 Cr ₹41.62 Cr ₹40.82 Cr ₹42.56 Cr ₹40.33 Cr ₹40.24 Cr ₹38.98 Cr
Other Expenses ₹135.13 Cr ₹157.46 Cr ₹147.38 Cr ₹125.07 Cr ₹111.32 Cr ₹137.69 Cr ₹122.63 Cr ₹132.27 Cr ₹117.46 Cr ₹140.57 Cr ₹123.67 Cr ₹146.7 Cr
Total Expenses ₹803.15 Cr ₹800.92 Cr ₹748.07 Cr ₹731.19 Cr ₹682.75 Cr ₹681.72 Cr ₹740.98 Cr ₹760.2 Cr ₹789.1 Cr ₹769.5 Cr ₹704.72 Cr ₹665.29 Cr
Profit Before Exceptional Items & Tax ₹564.8 Cr ₹436.8 Cr ₹408.67 Cr ₹362.38 Cr ₹391.32 Cr ₹394.13 Cr ₹379.82 Cr ₹300.32 Cr ₹432.69 Cr ₹371.76 Cr ₹347.06 Cr ₹253.99 Cr
Exceptional Items ₹0 -₹24.35 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹564.8 Cr ₹412.46 Cr ₹408.67 Cr ₹362.38 Cr ₹391.32 Cr ₹394.13 Cr ₹379.82 Cr ₹300.32 Cr ₹432.69 Cr ₹371.76 Cr ₹347.06 Cr ₹253.99 Cr
Total Tax Expense ₹144.35 Cr ₹104.61 Cr ₹106.68 Cr ₹93.13 Cr ₹101.32 Cr ₹99.01 Cr ₹98.11 Cr ₹77.39 Cr ₹111.28 Cr ₹94.95 Cr ₹89.54 Cr ₹66.41 Cr
Net Profit ₹420.45 Cr ₹307.85 Cr ₹302 Cr ₹269.26 Cr ₹290 Cr ₹295.12 Cr ₹281.71 Cr ₹222.92 Cr ₹321.41 Cr ₹276.81 Cr ₹257.53 Cr ₹187.58 Cr
Other Comprehensive Income ₹5.59 Cr ₹20.2 Lakh ₹1.41 Cr -₹73.1 Lakh -₹4.59 Cr ₹55.5 Lakh ₹1.58 Cr -₹46.5 Lakh -₹1.95 Cr ₹2.9 Lakh ₹62.1 Lakh -₹56.3 Lakh
Total Comprehensive Income ₹426.04 Cr ₹308.05 Cr ₹303.41 Cr ₹268.53 Cr ₹285.41 Cr ₹295.68 Cr ₹283.29 Cr ₹222.46 Cr ₹319.46 Cr ₹276.83 Cr ₹258.15 Cr ₹187.02 Cr
EBITDA (computed) ₹614.07 Cr ₹481.83 Cr ₹457.48 Cr ₹413.59 Cr ₹437.84 Cr ₹456.21 Cr ₹421.6 Cr ₹342.04 Cr ₹479.79 Cr ₹412.88 Cr ₹388.21 Cr ₹294.57 Cr
Basic EPS ₹25.52 ₹18.68 ₹18.33 ₹16.34 ₹17.60 ₹17.91 ₹17.10 ₹13.53 ₹19.51 ₹16.81 ₹15.64 ₹11.39
Diluted EPS ₹25.49 ₹18.68 ₹18.33 ₹16.34 ₹17.60 ₹17.91 ₹17.10 ₹13.53 ₹19.51 ₹16.80 ₹15.63 ₹11.39
Latest 12 quarters shown of 21 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Gland Pharma Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Gland Pharma Ltd

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.83%, foreign institutional investors hold 7.30%, domestic institutional investors hold 33.35%, retail and other public shareholders hold 7.52% of Gland Pharma Ltd. The company had 91,500 shareholders on record.

Promoters: 51.83%DII (Domestic Institutional): 33.35%FII (Foreign Institutional): 7.30%Retail & Others: 7.52%
Mar 2026
QUARTER
51.83% Promoters
33.35% DII (Domestic Institutional)
7.30% FII (Foreign Institutional)
7.52% Retail & Others
Promoter holding - history
Now 51.83% · Mar 2026High 58.36% · Nov 2020Low 51.83% · Jun 2024
50%52.5%55%57.5%60%Nov 2020Dec 2021Mar 2023Jun 2024Sep 2025Nov 2020: 58.36%Dec 2020: 58.36%Mar 2021: 58.25%Jun 2021: 58.14%Sep 2021: 58.02%Dec 2021: 58.00%Mar 2022: 58.00%Jun 2022: 57.87%Sep 2022: 57.86%Dec 2022: 57.86%Mar 2023: 57.86%Jun 2023: 57.86%Sep 2023: 57.86%Dec 2023: 57.86%Mar 2024: 57.86%Jun 2024: 51.83%Sep 2024: 51.83%Dec 2024: 51.83%Mar 2025: 51.83%Jun 2025: 51.83%Sep 2025: 51.83%Dec 2025: 51.83%Mar 2026: 51.83%58.36%51.83%51.83%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters51.83%51.83%51.83%51.83%51.83%51.83%
Public48.17%48.17%48.17%48.17%48.17%48.17%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Promoters51.83%51.83%57.86%57.86%58.00%58.25%
Public48.17%48.17%42.14%42.14%42.00%41.74%
Promoter change (YoY, %pts)+0.00-6.03+0.00-0.14-0.25-

Board & Governance of Gland Pharma Ltd

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Gland Pharma Ltd has 8 directors - 4 independent and 1 executive. The board is chaired by Srinivas Sadu.

DirectorPositionOn board sinceListed boards
Srinivas Sadu Executive Director · Chairperson 2019-04-25 1
UDO JAHANNES VETTER Non-Executive - Independent Director 2018-02-07 1
Essaji Goolam Vahanvati Non-Executive - Independent Director 2020-09-30 2
Satyanarayana Murthy Chavali Non-Executive - Independent Director 2018-11-20 2
Naina Lal Kidwai Non-Executive - Independent Director 2021-05-17 3
Jia Ai Zhang Non-Executive - Non Independent Director 2021-05-17 1
Wenjie Zhang Non-Executive - Non Independent Director 2024-08-30 1
Wei Huang Non-Executive - Non Independent Director 2024-11-04 1
Board Committees
CommitteeMembers
Audit Committee Satyanarayana Murthy Chavali (Chairperson), Essaji Goolam Vahanvati, UDO JAHANNES VETTER
Nomination and remuneration committee Satyanarayana Murthy Chavali (Chairperson), Essaji Goolam Vahanvati, UDO JAHANNES VETTER, Wei Huang
Stakeholders Relationship Committee Satyanarayana Murthy Chavali (Chairperson), Srinivas Sadu, Wenjie Zhang
Risk Management Committee Naina Lal Kidwai (Chairperson), Srinivas Sadu, Jia Ai Zhang, Ravi Shekar Mitra
Corporate Social Responsibility Committee Srinivas Sadu (Chairperson), Essaji Goolam Vahanvati, Jia Ai Zhang
ESOP Compensation Committee Satyanarayana Murthy Chavali (Chairperson), Essaji Goolam Vahanvati, UDO JAHANNES VETTER

Charges & Borrowings of Gland Pharma Ltd

Open charges
₹0
Satisfied charges
₹566.83 Cr
Breakdown by lending institutions
Syndicate Bank₹292.53 Cr
The Bank of Nova Scotia₹140.00 Cr
Icici Bank Limited₹100.00 Cr
Export Import Bank of India₹30.80 Cr
Technology Development Board₹3.50 Cr
Latest charge details
DateLenderAmountStatus
10 Sep 2012 Icici Bank Limited ₹100 Cr Satisfied
30 Jun 2012 Syndicate Bank ₹100 Cr Satisfied
06 Sep 2005 The Bank of Nova Scotia ₹140 Cr Satisfied
13 Dec 2004 Syndicate Bank ₹7.5 Cr Satisfied
09 Sep 2004 Export Import Bank of India ₹10 Cr Satisfied

Total charge records: 11 View all charges

Employees and EPFO Compliance at Gland Pharma Ltd

Gland Pharma Ltd has a workforce of 4,769 employees as of Mar 31, 2024.

Employee count
4,769
Active EPFO establishments
1
Employee growth
1.86%
Premium access

Employee and EPFO history for Gland Pharma Ltd

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Gland Pharma Ltd

Premium access

GST registrations and filing compliance for Gland Pharma Ltd

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Gland Pharma Ltd

Premium access

Credit ratings, litigation, and regulatory alerts for Gland Pharma Ltd

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Gland Pharma Ltd

Premium access

MSME payment history for Gland Pharma Ltd

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Gland Pharma Ltd

Premium access

Corporate group structure for Gland Pharma Ltd

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Gland Pharma Ltd

Premium access

MCA filings and documents for Gland Pharma Ltd

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Gland Pharma Ltd

Directors
15 Jun 2026
William Robert Keller was appointed as a Additional Director on 15 Jun 2026 & has been associated with this company since 2 months 4 days.
Activity
28 Aug 2025
Gland Pharma Ltd last Annual general meeting of members was held on 28 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Gland Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
04 Nov 2024
Wei Huang was appointed as a Director on 04 Nov 2024 & has been associated with this company since 1 year 9 months.
Directors
30 Aug 2024
Wenjie Zhang was appointed as a Director on 30 Aug 2024 & has been associated with this company since 1 year 11 months.
Directors
17 May 2021
Jia Ai Zhang was appointed as a Director on 17 May 2021 & has been associated with this company since 5 years 3 months.

Recent News on Gland Pharma Ltd

Frequently Asked Questions about Gland Pharma Ltd

Gland Pharma Ltd is an active public limited company in the healthcare sector based in Medchal Malkajgiri District Hyderabad, Telangana, India. It was incorporated on 20 March 1978 (48+ years old) and is registered under CIN L24239TG1978PLC002276. Listed on BSE: 543245 and NSE: GLAND. The company has 4,769 employees.

Gland Pharma Ltd reported revenue of ₹6,430.65 Cr for FY 2026 (up 14.5% YoY) based on consolidated NSE filings.

The current directors of Gland Pharma Ltd are:

The primary industry of Gland Pharma Ltd is healthcare. The company specifically operates in medical and laboratory equipment. The company is currently active in this sector.

Yes. Gland Pharma Ltd is listed on both BSE (code: 543245) and NSE (symbol: GLAND).

Gland Pharma Ltd can be reached at the registered office: Sy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, AmmaM, Medchal Malkajgiri District Hyderabad, Telangana, India – 500043, or through the website glandpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available